<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629381</url>
  </required_header>
  <id_info>
    <org_study_id>2010-024338-43</org_study_id>
    <nct_id>NCT01629381</nct_id>
  </id_info>
  <brief_title>Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy</brief_title>
  <acronym>ERIKA</acronym>
  <official_title>Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy: a Randomized Double-blind Trial (ERIKA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padua</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objective: To assess the value of Rivaroxaban for the prevention of venous
      thromboembolism (VTE) after knee arthroscopy (KA) taking the placebo as standard of
      reference.

      Study Population: Patients undergoing therapeutic KA at the study Centers, irrespective of
      the type and duration of the procedure, will be eligible for the study.

      Study Design: Multicenter, randomized, double blind superiority, phase II trial comparing two
      arms:

        -  (R-7d) Rivaroxaban (10 mg od os) for 7 days

        -  (PL-7d) Placebo for 7 days.

      Follow-up: 3-month period after the randomization

      Standard of Reference:Placebo will be the standard of reference in accordance to
      international guidelines

      Study length May 2012-December 2012

      Total patients number: 500 patients

      Primary Efficacy End-Point: Occurrence in the 3-month period after the randomization of at
      least one of the following events, objectively proven (by means of CCDU; multi-slice chest
      TC-angio; autopsy, if necessary, or clinical ground):

        -  All-cause mortality

        -  Symptomatic VTE

        -  Asymptomatic proximal DVT

      Secondary Efficacy End-point:

      â€¢ Combined incidence of all DVT plus symptomatic PE

      Primary Safety End-point: Incidence of major bleedings.

      Secondary Safety End-point: Overall incidence of bleeding
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatments will be administered postoperatively (1st dose 8-10 hours after procedure),
      for prevention of venous thromboembolism after KA.

      A bilateral whole-leg colour-coded Doppler ultrasonography (CCDU) is scheduled for all
      patients at 7 (+1) days of follow-up; additionally, CCDU was due if the patients developed
      symptoms or signs suggestive of venous thromboembolism earlier.

      Statistical &amp; Analytical Plan and Methodology: In the absence of prophylaxis the incidence of
      venous thromboembolism (primary efficacy end-point) after KA, as assessed by CCDU, is about
      8.0% (combining weighted results of various paper). Prophylaxis with low-molecular weight
      heparins assures approximately a 60-70% relative risk reduction in this setting. Based on the
      findings of published trials investigating the efficacy of Rivaroxaban for prevention of
      venous thromboembolism after elective hip and knee surgery, when using a low-molecular-weight
      heparin as comparator, investigators can speculate that Rivaroxaban will further reduce this
      incidence (at least 1.2%).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of symptomatic venous thromboembolism plus asymptomatic proximal vein thrombosis and all-cause mortality</measure>
    <time_frame>3-month period</time_frame>
    <description>During the scheduled visit in case of suspected DVT a bilateral whole-leg colour-coded Doppler ultrasonography (CCDU) is scheduled for all patients at 7 (+1) days of follow-up; additionally, CCDU will be performed if the patients develop symptoms or signs suggestive of venous thromboembolism earlier; in case of suspected PE a multi-slice chest TC-angio is arranged; in case of death for all cause autoptic findings are requested or, if necessary, clinical ground is considered. A follow-up visit is planned 3-month period after the randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleedings</measure>
    <time_frame>3 months</time_frame>
    <description>Major bleeding include: clinically overt haemorrhage associated with haemoglobin drop of at least 2 g/L or requiring the transfusion of two or more units of packed red-blood cells; retroperitoneal or intracranial events; bleeding requiring re-intervention; and hemarthrosis with a joint drainage of more than 450 millilitres of blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined incidence of all DVT plus symptomatic PE</measure>
    <time_frame>3 months</time_frame>
    <description>As described for the assessment of the primary efficacy outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of bleeding</measure>
    <time_frame>3 months</time_frame>
    <description>As described for the primary safety outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Rivaroxaban 10 mg od for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo od for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>10 mg os once daily for 1 week</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>10 mg os once daily for 1 week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patient (18 years and older)

          2. Knee arthroscopy not combined with open surgery.

          3. Patients eligible for surgical treatment.

          4. Patients are willing and able to continue study participation to ensure completion of
             all procedures and observations required by the study.

          5. Written informed consent

        Exclusion Criteria:

          1. Diagnostic arthroscopy

          2. Patients concomitantly treated systemically with strong concurrent CYP3A4 and
             P-gp-inhibitors, i.e. azole-antimycotics or HIV protease inhibitors.

          3. Hypersensitivity to the active substance or to any of the excipients of study drug

          4. Pregnant women or breast-feeding.

          5. Hepatic disease associated with coagulopathy and clinically relevant bleeding risk

          6. Known thrombophilia (hereditary or acquired)

          7. Mandatory anticoagulation.

          8. Known severe bleeding tendency

          9. Clinically significant active bleeding.

         10. Severe renal failure (GFR&lt;30mL/min/1.73m2)

         11. Patients participating in another clinical trial.

         12. Recent mayor surgery (6 to 12 weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Camporese, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unit of Angiology, University Hospital of Padua, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Camporese, MD</last_name>
    <phone>+393479747221</phone>
    <email>giuseppe.camporese@sanita.padova.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franco Noventa, MD</last_name>
    <phone>+393358768685</phone>
    <email>franco.noventa@unipd.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thrombosis Center &amp; Knee Arthroscopy and Sports Medicine Center, Humanitas Clinical Insitute</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrado Lodigiani, MD</last_name>
      <phone>+39335265699</phone>
      <email>corrado.lodigiani@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Corrado Lodigiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Corrado Bait, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedics and Traumatology, University Hospital &quot;Galliera&quot; of Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Mazzola, MD</last_name>
      <phone>+393472321691</phone>
      <email>claudio.mazzola@galliera.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Mazzola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, University Hospital of Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierpaolo Di Micco, MD</last_name>
      <phone>+393398078146</phone>
      <email>pdimicco@libero.it,</email>
    </contact>
    <contact_backup>
      <last_name>Paolo Dimaro, MD</last_name>
      <email>paolo.dimaro@fastwebnet.it</email>
    </contact_backup>
    <investigator>
      <last_name>Pierpaolo Di Micco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedics and Traumatology, University Hospital of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giacomo Zanon, MD</last_name>
      <email>zanon.g@libero.it</email>
    </contact>
    <contact_backup>
      <last_name>Matteo Marullo, MD</last_name>
      <email>matteomarullo@hotmail.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giacomo Zanon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matteo Marullo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Section of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia</name>
      <address>
        <city>Perugia</city>
        <zip>06123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Becattini, MD</last_name>
      <phone>+393478752203</phone>
      <email>cecilia.becattini@unipg.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Cristina Vedovati, MD</last_name>
      <phone>+393288518290</phone>
      <email>mcristinaved@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Cecilia Becattni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Hospital of Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Imberti, MD</last_name>
      <phone>+393384547502</phone>
      <email>d.imberti@ausl.pc.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unit of Angiology, Department of Internal Medicine, Azienda Ospedaliera - IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Ghirarduzzi, MD</last_name>
      <phone>+393391241681</phone>
      <email>ghirarduzzi.angelo@asmn.re.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Rosaria Veropalumbo, MD</last_name>
      <phone>+3289139222</phone>
      <email>MariaRosaria.Veropalumbo@asmn.re.it</email>
    </contact_backup>
    <investigator>
      <last_name>Angelo Ghirarduzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rosaria Veropalumbo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopedics and Surgery of the Hand, Catholic University &quot;Sacro Cuore&quot;</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Bosco, PhD, MD</last_name>
      <phone>+393473312952</phone>
      <email>mbosco@rm.unicatt.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unit of Angiology, Hospital of Venice</name>
      <address>
        <city>Venice</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristiano Bortoluzzi, MD</last_name>
      <phone>+393478163641</phone>
      <email>crisbort@libero.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Parisi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristiano Bortoluzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2012</study_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padua</investigator_affiliation>
    <investigator_full_name>Giuseppe Camporese</investigator_full_name>
    <investigator_title>MD, Principal Investigator, Coordinator of Emergency Section at the Unit of Angiology, University Hospital of Padua</investigator_title>
  </responsible_party>
  <keyword>knee arthroscopy</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 19, 2015</submitted>
    <returned>November 18, 2015</returned>
    <submitted>November 25, 2015</submitted>
    <returned>December 30, 2015</returned>
    <submitted>January 4, 2016</submitted>
    <returned>February 4, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

